Keros Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Keros Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
  • Keros Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$58.7M, a 35.5% decline year-over-year.
  • Keros Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$204M, a 31.3% decline year-over-year.
  • Keros Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$170M, a 48% decline from 2022.
  • Keros Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$115M, a 104% decline from 2021.
  • Keros Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$56.4M, a 20.8% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$170M -$55.2M -48% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-28
2022 -$115M -$58.4M -104% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-28
2021 -$56.4M -$9.72M -20.8% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 -$46.7M -$36.1M -342% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-09
2019 -$10.6M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.